Geovax receives notice of allowance for malaria vaccine patent

Patent covers multiple component vaccine for both prevention and treatment atlanta, ga, aug. 28, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the u.s. patent and trademark office has issued a notice of allowance for patent application no. 17/726,254 titled “compositions and methods for generating an immune response to treat or prevent malaria”.
GOVX Ratings Summary
GOVX Quant Ranking